# Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations

> **NCT06955325** · PHASE3 · NOT_YET_RECRUITING · sponsor: **The First Affiliated Hospital of Guangzhou Medical University** · enrollment: 270 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Icotinib
- **DRUG:** Rezivertinib
- **DRUG:** Ensartinib
- **DRUG:** Benmelstobart

## Key facts

- **NCT ID:** NCT06955325
- **Lead sponsor:** The First Affiliated Hospital of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05
- **Primary completion:** 2030-12
- **Final completion:** 2035-12
- **Target enrollment:** 270 (ESTIMATED)
- **Last updated:** 2025-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06955325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06955325, "Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06955325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*